Earnings calls

Glaxosmi. Pharma concall ledger

Every earnings call for GLAXO — management tone, guidance, KPIs and promise tracking, quarter by quarter.

GLAXO · 3 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 09 Feb 2026Call held 09 Feb 2026

GLAXO Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹1,000 cr+8% YoYEBITDA Margin35.9%PAT Margin27.3%

Revenue (Standalone) ₹1,000 cr (+8% YoY); EBITDA Margin 35.9%; PAT Margin 27.3%. Consolidated revenue grew ~10% to cross INR 1,000 crores for the first time in a quarter.

Read full transcript & analysis

Q4 FY25Published 13 May 2025Call held 13 May 2025

GLAXO Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹3,723 cr+9% YoYEBITDA₹1,169 cr+30% YoYEBITDA Margin31%

Revenue (Full Year) ₹3,723 cr (+9% YoY); EBITDA (Full Year) ₹1,169 cr (+30% YoY); EBITDA Margin (Full Year) 31%. Full year revenue of INR 3723 crores, up 9% YoY.

Read full transcript & analysis

Q3 FY25Published 14 Feb 2025Call held 14 Feb 2025

GLAXO Q3 FY25 Earnings Call Transcript & Analysis

EBITDA₹290 cr+33% YoYEBITDA Margin30.7%

EBITDA ₹290 cr (+33% YoY); EBITDA Margin 30.7%. Revenue grew 18% YoY, driven by double-digit growth across all business segments.

Read full transcript & analysis